Latest Updates

11/10/2017 - Metastatic/Advanced Breast Cancer

9/7/2017 - Ovarian Cancer

9/6/2017 - Bladder, Urethra, Penis Cancers

12/5/2016 - Acute Leukemias

11/28/2016 - Multiple Myeloma

8/16/2016 - Metastatic NSCLC

7/17/2015 - Metastatic NSCLC
  • FDA approval of treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 substitution mutations

7/14/2015 - Early Breast Cancer

6/2/2015 - Multiple Myeloma

5/20/2015 - CRC Medical Management
  • Approval of ramucirumab for use in combination with FOLFIRI for the treatment of patients with metastatic CRC whose disease has progressed on a first line bevacizumab-, oxaliplatin- and fluoropyrimidine-containing regimen

4/10/2015 - CML

4/8/2015 - Metastatic NSCLC
  • PD-1 inhibitor nivolumab approved for patients with metastatic squamous NSCLC with progression on or after platinum-based chemotherapy
  • Expanded table of ongoing phase III clinical trials with immune checkpoint inhibitors

2/25/2015 - Metastatic/Advanced Breast Cancer

1/6/2015 - Metastatic NSCLC
  • New FDA approval of ramucirumab for use in combination with docetaxel for the treatment of patients with metastatic NSCLC with disease progression on or after platinum-based chemotherapy

12/17/2014 - Metastatic NSCLC
  • Current guidance from the NCCN on maintenance therapy
  • Data on bevacizumab plus pemetrexed as maintenance therapy following platinum-based chemotherapy

11/6/2014 - Hepatocellular Carcinoma

9/22/2014 - CRC Medical Management

8/22/2014 - Metastatic NSCLC
  • Novel agents with demonstrated efficacy in squamous cell histology
  • New discussion on mechanisms of resistance to TKIs
  • Review of multivariate serum protein test classification to guide second-line treatment choice in patients with wild-type or unknown EGFR status
  • New discussion about TKI resistance in ALK-rearranged patients who develop resistance to crizotinib
  • Review of data from the REVEL study of docetaxel and ramucirumab vs docetaxel as second-line therapy for metastatic NSCLC following disease progression after one prior platinum-based therapy
  • FDA Breakthrough Therapy designation for dabrafenib in patients with metastatic BRAF V600E–positive NSCLC
  • Updated with ongoing clinical trials investigating promising immune checkpoint inhibitors

7/31/2014 - PTCL and CTCL

6/23/2014 - Locally Advanced Breast Cancer

6/2/2014 - Kidney Cancer

5/14/2014 - Metastatic NSCLC
  • Updated with accelerated FDA approval of ceritinib for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib

2/21/2014 - Prostate Cancer

2/11/2014 - Metastatic NSCLC
  • Summary bullets added to show key highlights for quick point-of-care reference 
  • Updated to reflect current NCCN guideline recommendations for the treatment of NSCLC

1/10/2014 - Metastatic NSCLC
  • Updated with November 20, 2013, FDA regular approval of crizotinib for the treatment of patients with ALK-positive metastatic NSCLC

10/31/2013 - Metastatic/Advanced Breast Cancer

10/29/2013 - Chronic Lymphocytic Leukemia

9/12/2013 - Bladder, Urethra, Penis Cancers
  • Updated to include new results from studies of chemotherapy for bladder cancer, including regimens with or without radiation therapy 
  • Updated to include new prognostic factors for patients with penile cancer 

8/23/2013 - CRC Medical Management

8/14/2013 - Acute Leukemias

7/17/2013 - Metastatic NSCLC
  • Updated with information on the approval of afatinib for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitutions as detected by a concurrently FDA-approved EGFR mutation test (Therascreen EGFR RGQ PCR Kit)
  • Updated with discussion on and evidence basis for targeting the MET, ROS1, RET, and other novel molecular pathways in NSCLC 
  • Updated with results from:
    • LUX-Lung 1, 3, and 6 trials that show improved outcomes with afatinib
    • PointBreak trial comparing carboplatin/paclitaxel/bevacizumab to carboplatin/pemetrexed/bevacizumab 
    • LUME Lung trial showing increased PFS for nintedanib
  • Journal Highlight: on the CAP, IASLC, and AMP molecular testing guidelines for lung cancer

6/28/2013 - CRC Medical Management
  • Approval of regorafenib for the treatment of certain previously treated patients with metastatic CRC

6/7/2013 - Metastatic NSCLC
  • Updated with the joint evidence-based guideline from the IASLC, CAP, and AMP on molecular testing for the selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors
  • Updated with the FDA approval for cobas EGFR Mutation Test as a companion diagnostic for erlotinib patient selection
  • Updated with the FDA approval for an expanded indication for erlotinib for the first-line treatment of of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test

5/28/2013 - Metastatic NSCLC
  • Updated with the joint evidence-based guideline [drug: l1] [drug: ab2] from the IASLC, CAP, and AMP on molecular testing for the selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors 

4/25/2013 - Palliative Care

4/17/2013 - Biliary Cancers
  • Updated with NCCN guidelines on gemcitabine/cisplatin combination therapy for patients with unresectable or metastatic biliary cancer
  • Updated with clinical trial data on panitumumab with chemotherapy and erlotinib with bevacizumab

4/3/2013 - Bone Cancer

3/25/2013 - Multiple Myeloma
  • Updated with FDA approval of pomalidomide for patients with relapsed or refractory multiple myeloma who have received at least 2 previous therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

3/25/2013 - CRC Medical Management
  • FDA approval of bevacizumab in second-line therapy for patients with metastatic colorectal cancer who progressed on a first-line bevacizumab-containing regimen

3/20/2013 - Screening for Colorectal Cancer

3/18/2013 - Gastric Cancer

3/15/2013 - Bladder, Urethra, Penis Cancers
  • Updated with NCCN recommendations on the use of pelvic CT 
  • Updated with NCCN recommendations on Bacillus Calmette-Guérin and mitomycin for patients with noninvasive tumors 
  • Updated with NCCN recommendations on chemoradiation for patients with invasive, nonmetastatic bladder cancer 
  • Updated with NCCN recommendations on chemotherapy for patients with invasive bladder cancer 

2/11/2013 - Thyroid Cancer Management

11/28/2012 - CRC Medical Management
  • Approval of regorafenib for the treatment of certain previously treated patients with metastatic CRC

11/1/2012 - Metastatic NSCLC
  • Updated with FDA approval of albumin-bound paclitaxel to treat adult patients with locally advanced or metastatic NSCLC as first-line treatment in combination with carboplatin, in those who are not candidates for curative surgery or radiation therapy

8/20/2012 - CRC Medical Management
  • Approval of aflibercept for use in combination with FOLFIRI in patients with metastatic colorectal cancer whose tumors progress after or are resistant to oxaliplatin-based chemotherapy
  • Announcement of expanded use of cetuximab (in combination with FOLFIRI) as a first-line treatment for metastatic colorectal cancer in patients with confirmed EGFR expression and wild-type KRAS

6/12/2012 - Multiple Myeloma
  • Updated with FDA statement on association of lenalidomide use with secondary primary malignancies

11/11/2011 - CRC Medical Management

11/8/2011 - Bladder, Urethra, Penis Cancers
  • Updated data on prognosis following postoperative bladder cancer recurrence 
  • Updated results from the BA06 30894 trial of neoadjuvant CMV 
  • Updated data on adjuvant therapy with paclitaxel/gemcitabine/cisplatin compared with observation for high-risk resected bladder cancer 
  • Updated information on the use of hyperbaric oxygen to treat tissue necrosis due to brachytherapy in penile cancer 

11/8/2011 - Hepatocellular Carcinoma

11/1/2011 - Nonovarian Cancer
  • Content reviewed and validated

10/28/2011 - Metastatic NSCLC
  • Accelerated approval of crizotinib in advanced ALK-positive NSCLC
  • Updated findings from the phase III EURTAC trial of first-line erlotinib vs chemotherapy

10/14/2011 - Metastatic/Advanced Breast Cancer

9/26/2011 - Multiple Myeloma
  • Updated with new data on varying lenalidomide combination regimens for relapsed/refractory disease
  • Updated with new data on the use of lenalidomide maintenance therapy
  • Updated with new data on varying bortezomib combination regimens for newly diagnosed multiple myeloma

9/6/2011 - Acute Leukemias

12/10/2010 - Hepatocellular Carcinoma
  • Expanded discussion on management of adverse events of treatment with sorafenib
  • Updated data from clinical trial of adjuvant therapy with [drug: sorafenib] following TACE

12/7/2010 - Screening for Colorectal Cancer
  • Results from a large, randomized, multicenter study in the UK showing reduced CRC incidence and mortality with flexible sigmoidoscopy screening
  • Findings reported in 2010 comparing sensitivity/specificity of GT vs quantitative FIT in 777 average-risk patients

12/6/2010 - Metastatic NSCLC
  • Phase III data of nab-paclitaxel plus carboplatin as first-line therapy in advanced NSCLC
  • Approval of pemetrexed as maintenance therapy
  • Phase III findings of doublet chemotherapy in elderly patients with advanced NSCLC and poor performance score
  • Role of novel agents such as crizotinib and figitumumab in advanced NSCLC

12/3/2010 - Supportive Care: Nausea, Vomiting, and Diarrhea
  • Updated NCCN guideline
  • Updated data on trials, guidelines, and recommendations

12/2/2010 - CRC Medical Management
  • Added new data from CRYSTAL and OPUS trials regarding the role of BRAF mutation in determining therapy with EGFR-targeting agents
  • Updated with findings from the PRIME study, a global, open-label phase III study of first-line treatment with FOLFOX4 with or without panitumumab in metastatic colorectal cancer
  • Updated data from COIN study evaluating XELOX or modified FOLFOX6 plus cetuximab in patients with wild-type KRAS tumors
  • Findings from newer studies of adjuvant therapy in stage II/III disease
  • Added information on available tests for genetic signatures for prognosis and prediction

12/2/2010 - Neuroendocrine Tumors
  • Content reviewed and recertified

12/2/2010 - Esophageal Cancer
  • Updated with findings from trials of neoadjuvant chemoradiotherapy vs surgery
  • Quality of life results from ToGA trial
  • Trial results with neoadjuvant CRT plus cetuximab

12/2/2010 - Molecular Diagnostics
  • Updated INTEREST trial data
  • Updated study data
  • Updated references

12/2/2010 - Melanoma: Medical Management
  • Randomized phase III trial testing anti-CTLA4 blockade with ipilimumab---first to demonstrate overall survival benefit
  • Updates on novel therapeutic strategies in clinical trials

12/2/2010 - Early-Stage NSCLC
  • Discussion of National Lung Cancer Screening Trial findings of CT vs chest x-ray in former and current heavy smokers
  • Role of maximum oxygen consumption (VO2max) in predicting postoperative complications following lung resection for NSCLC

12/2/2010 - Non-Hodgkin’s Lymphoma
  • Maintenance rituximab following induction chemoimmunotherapy
  • Emerging therapies (galiximab, epratuzumab, bortezomib, enzastaurin, temsirolimus, and lenalidomide)
  • Activity of bendamustine in the setting of rituximab relapse or refractoriness
  • Bendamustine combined with rituximab as first-line treatment in older patients with mantle cell lymphoma

12/2/2010 - Ovarian Cancer
  • Discussion on the use of maintenance bevacizumab in ovarian cancer

12/1/2010 - Management of Stage III NSCLC
  • The role of surgery in treating patients with stage III lung cancer
  • Current treatment of stage III lung cancer with chemotherapy and radiation therapy
  • The optimal incorporation of targeted therapies into therapies for stage III lung cancer

12/1/2010 - Small-Cell Lung Cancer
  • Phase II and III trials of picoplatin in platinum-refractory/resistant or progressive SCLC
  • Analysis of the effect of prophylactic cranial irradiation on global health status and functioning scores

12/1/2010 - Gastric Cancer
  • Based on results from ToGA trial, trastuzumab new standard of care for patients with HER2-overexpressing metastatic gastric cancer
  • Updated findings from recent phase III trials of current chemotherapy regimens for advanced/metastatic gastric cancer

12/1/2010 - Surgical Management of Melanoma
  • AJCC Cancer Staging Manual 7th edition

12/1/2010 - Bladder, Urethra, Penis Cancers
  • Updated trial data

12/1/2010 - CRC Surgery
  • Updated with AJCC 7th edition staging definitions

11/30/2010 - Palliative Care
  • Updated to include results from a landmark study providing evidence supporting early palliative care involvement

11/30/2010 - Nonmelanoma Skin Cancers
  • Romidepsin, newly FDA-approved systemic treatment for relapsed/refractory cutaneous T-cell lymphoma.
  • Phase I clinical trial data on GDC-0449, a hedgehog pathway inhibitor for treatment of advanced basal cell carcinoma; phase II trial ongoing 

11/30/2010 - Cardiotoxicity
  • Newly published data on radiation-related cardiac disease
  • Guidance from the National Cancer Institute’s Investigational Drug Steering Committee on management of hypertension associated with antineoplastic agents

11/30/2010 - Nonovarian Cancer
  • Updates in the International Federation of Gynecology and Obstetrics (FIGO)/American Joint Committee on Cancer (AJCC) staging systems
  • Updates in currently enrolling clinical trials in nonovarian cancers

11/30/2010 - HIV and Cancer
  • Content reviewed and recertified

11/30/2010 - Anticancer Treatment Pulmonary Toxicity
  • Discussion of amrubicin
  • Discussion of pemetrexed

11/25/2010 - Neutropenia Management
  • Updated study and trial data
  • Updated NCCN reference

11/23/2010 - Lung Cancer Screening
  • Data regarding the NLST of CT vs chest x-ray among current and former heavy smokers

11/23/2010 - Oncologic Emergencies
  • The international TLS expert consensus panel recommendations for the evaluation of risk and prophylaxis of TLS
  • Tolvaptan for the treatment of clinically significant hypervolemic and euvolemic hyponatremia

11/23/2010 - Special Situations in Breast Diseases
  • Updated NCCN reference
  • Updated trial data and information

11/19/2010 - Locoregionally Advanced H&N Cancer

Updated with the following:

  • Use of dysphagia-sparing intensity-modulated radiotherapy
  • Utility of PET/CT in the assessment of treatment response following radiotherapy
  • Discussion of the interplay between HPV-positive tumors, smoking status, and advanced nodal disease

11/18/2010 - Recurrent or Metastatic Head and Neck Cancer
  • Updated the incidence of human papillomavirus–associated HNSCC
  • Updated with recently published studies investigating capecitabine in metastatic or recurrent HNSCC

11/18/2010 - Cancer- and Chemotherapy-Related Anemia
  • Updated trial data
  • Updated ASCO/ASH recommendations
  • Updated NCCN guideline reference

11/17/2010 - Molecular Biology
  • FDA approval of sipuleucel-T

11/17/2010 - Psychosocial Issues in Cancer
  • Updated with new meta-analyses on psychological distress and depression
  • Updated with new data on the financial burden of cancer and its treatment
  • Updated with new data on obtaining a patient’s advance directive

11/17/2010 - Management of Thymomas
  • Content reviewed and recertified

11/17/2010 - Prostate Cancer
  • Results of CALGB 90401 trial
  • Results of ASCENT-2 trial
  • Results of IMPACT trial
  • Updated results of PROSTVAC-VF
  • Updated results of phase III denosumab trial

11/17/2010 - Myelodysplastic Syndromes
  • Discussion of human 5q- syndrome
  • Updated with data from MDS-004 study
  • New black box warning for deferasirox concerning risk for renal failure, hepatic failure, and gastrointestinal hemorrhage

11/17/2010 - Cancer of Unknown Primary Site
  • Content reviewed and recertified

11/17/2010 - Testicular Cancer
  • Additional information on standard management approaches for early-stage nonseminoma
  • Updated trial data
  • Updated NCCN reference

11/17/2010 - Pancreatic Adenocarcinoma
  • Updated with results from the landmark PRODIGE 4/ACCORD 11 study of FOLFIRINOX

11/17/2010 - Nutritional Support and Oncology
  • Content reviewed and recertified

11/17/2010 - Multiple Myeloma
  • Content reviewed and recertified

11/17/2010 - Chronic Lymphocytic Leukemia
  • Content reviewed and recertified

11/17/2010 - GIST
  • Updated with a new table outlining prognostic factors for disease progression and recently presented studies on the future of directed therapy in GIST

11/17/2010 - Early Breast Cancer
  • Updates on genetic assay results
  • Expansion and updates on trial data
  • Added data on triple-negative breast cancer
  • Update includes most recently updated NCCN guideline reference

11/17/2010 - CML
  • Content reviewed and recertified

11/17/2010 - Hodgkin's Lymphoma
  • Postremission imaging
  • Treatment of early-stage Hodgkin’s lymphoma
  • Treatment of nodular lymphocyte-predominant Hodgkin’s lymphoma
  • New agents for salvage treatment of Hodgkin’s lymphoma

11/17/2010 - Kidney Cancer
  • Content reviewed and recertified

11/17/2010 - Soft Tissue Sarcomas
  • Updated with discussion of PET scans with [drug: (18)F]fluorodeoxyglucose to predict response to neoadjuvant regimens
  • Updated with discussion of new agents that have demonstrated promise for the treatment of soft tissue sarcomas

11/17/2010 - Locally Advanced Breast Cancer
  • Content reviewed and recertified

11/17/2010 - Bone Cancer
  • Updated with new data on adding muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma
  • Updated with new data on the use of insulin-like growth factor-1 receptor antagonists to treat Ewing’s sarcoma

11/17/2010 - Breast Cancer Screening
  • Content reviewed and recertified

11/12/2010 - Acute Leukemias
  • Updated to reflect voluntary withdrawal of gemtuzumab ozogamicin
  • Expanded discussion and updated data on treatment strategies for ALL, including
    • Optimal dose of anthracyclines induction therapy
    • Clofarabine in AML
    • Novel agents and regimens, including sorafenib and sapacitabine
  • Updated results from trials of imatinib mesylate and dasatinib in Ph+ ALL
  • Updated results from studies of hyper-CVAD plus rituximab in B-lineage ALL

10/27/2010 - Multiple Myeloma
  • Updated with new data on first-line RVD
  • Updated with new data on the use of lenalidomide maintenance therapy

10/25/2010 - Metastatic/Advanced Breast Cancer
  • FDA approval of eribulin mesylate for the treatment of patients with metastatic breast cancer who have previously received an anthracycline and a taxane in either the adjuvant or metastatic setting and at least 2 chemotherapeutic regimens for the treatment of metastatic disease based on EMBRACE trial results
  • Results of the EMBRACE trial
  • Updated NCCN breast cancer guideline reference (March 2010)
  • New ASCO/CAP guideline for ER/PR testing (April 2010)
  • New section on the classification and treatment approaches for patients with triple negative breast cancer
  • FDA approval of lapatinib in combination with letrozole for the treatment of hormone receptor–positive/HER2-positive postmenopausal advanced breast cancer patients

10/22/2010 - Chronic Lymphocytic Leukemia
  • Updated with new prognosis data for patients with p53 mutations
  • Updated with new data on first-line treatment with purine analogue combinations
  • New data on the use of alemtuzumab in combination with fludarabine for relapsed CLL
  • Updated with new data on reduced-intensity conditioning with allogeneic stem cell transplantation
  • FDA indication for rituximab with standard FC chemotherapy for CLL

9/27/2010 - Kidney Cancer
  • Added details of several new trials
  • Updated NCCN reference

8/19/2010 - Acute Leukemias Updated to reflect voluntary withdrawal of gemtuzumab ozogamicin.

7/13/2010 - Prostate Cancer
  • FDA approval of cabazitaxel

7/1/2010 - CML
  • New FDA approval of nilotinib for newly diagnosed chronic-phase chronic myeloid leukemia
  • Updated with new phase III data on dasatinib as initial therapy for chronic-phase chronic myeloid leukemia

5/11/2010 - Prostate Cancer
  • Results of the TROPIC trial
  • Results from phase III denosumab trial
  • FDA approval of Sipuleucel-T
  • Updated NCCN guidelines reference
  • Updated published references

4/15/2010 - CRC Medical Management Updated NCCN guidelines and new studies on the role of molecular markers to predict efficacy of treatment

4/14/2010 - Myelodysplastic Syndromes
  • Discussion of mouse model for human 5q- syndrome
  • Updated with data from MDS-004 study
  • New black box warning for deferasirox concerning risk for renal failure, hepatic failure, and gastrointestinal hemorrhage

4/13/2010 - Metastatic/Advanced Breast Cancer
  • Updated to include the recent FDA approval of the use of lapatinib in combination with letrozole for hormone receptor–positive/HER2-positive postmenopausal advanced breast cancer patients
  • Updated results of the RIBBON-2 trial
  • Updated NCCN guideline reference

4/13/2010 - Chronic Lymphocytic Leukemia
  • Updated with long-term survival analysis of the C9011 study
  • Updated with extended follow-up data from the CLL8 study
  • New FDA indication for rituximab with standard FC chemotherapy for CLL

3/24/2010 - Kidney Cancer Update includes the most recently published NCCN guideline reference.

3/22/2010 - Melanoma: Medical Management Updated to reflect updated AJCC Cancer Staging Manual, 7th Edition, and new information on novel therapeutic approaches.

3/22/2010 - Cancer- and Chemotherapy-Related Anemia
  • Updated NCCN guideline reference

3/19/2010 - CML
  • Updated with 8-year follow-up data on imatinib in chronic-phase chronic myeloid leukemia
  • Updated with new data on nilotinib as initial therapy for chronic myeloid leukemia
  • Updated with new data on dasatinib as initial therapy for chronic myeloid leukemia

3/18/2010 - Multiple Myeloma
  • Updated dosing recommendations for bortezomib in patients with moderate or severe hepatic impairment

3/18/2010 - Non-Hodgkin’s Lymphoma
  • Updated to reflect new understanding of the FLIPI2 score as a prognostic tool
  • New data on the use of radioimmunotherapy with combination chemotherapy in follicular lymphoma
  • Addition of pralatrexate as a therapy option for peripheral T-cell lymphoma

3/18/2010 - Breast Cancer Screening
  • Updated to include breast cancer staging information
  • Updated to include US Preventive Services Task Force recommendations

3/16/2010 - Early Breast Cancer
  • Update includes most recently updated NCCN guideline reference.

3/16/2010 - Locally Advanced Breast Cancer

  • Update includes the most recently updated NCCN guideline reference.

12/3/2009 - Metastatic NSCLC New ASCO clinical practice guideline update for chemotherapy for stage IV NSCLC.

11/24/2009 - Nonmelanoma Skin Cancers
  • Romidepsin, newly FDA-approved systemic treatment for relapsed/refractory cutaneous T-cell lymphoma.

11/23/2009 - Chronic Lymphocytic Leukemia Added details of US FDA approval of ofatumumab in patients with fludarabine- and alemtuzumab-refractory disease.

11/6/2009 - Kidney Cancer Added details of FDA approval of pazopanib for advanced renal cell carcinoma.